U.S. Anti-Inflammatory Biologics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitor, and Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2023-2030

The U.S. anti-inflammatory biologics market size was worth USD 51.57 billion in 2022 and is projected to grow at a CAGR of 6.1% during the forecast period. 

Anti-inflammatory biologics are manufactured targeting specific inflammatory cells, cytokines, and cellular interactions mediating inflammatory-related tissue damage. The U.S. has observed a significant rise in the prevalence of inflammation-related diseases, which has increased the number of adults seeking treatment for these diseases. For instance, according to the CDC, in the U.S., the prevalence of asthma was 24,963,874 in 2021.

The surge in the introduction of drugs, strong healthcare infrastructure, growing focus of market players in the development of drugs, and the increasing geriatric population in the country drives the growth in the adoption of anti-inflammatory biologics.

The COVID-19 pandemic increased the adoption of these biologics by doctors in the country. The positive growth was attributed to the increase in patients with psoriasis and other inflammation disorders.

U.S. Anti-Inflammatory Biologics Market Trends

Strong Focus on Development of Novel Anti-inflammatory Biologics to Drive Market Expansion

In recent years, the market has witnessed a growing shift from traditional drugs to biologics due to the various benefits associated with these biologics. Furthermore, the key players focus on developing biologics to treat various chronic conditions, such as arthritis and multiple sclerosis, to attract a wider customer base.

In March 2023, Incyte announced new results of 104-week from the pivotal Phase 3 TRuE-V clinical trial program evaluating Opzelura (ruxolitinib) cream in adult patients 12 years of age and older suffering from nonsegmental vitiligo at the 2023 American Academy of Dermatology (AAD) Annual Meeting.

U.S. Anti-Inflammatory Biologics Market Growth Factors

Surging Inflammatory Diseases Incidence to Boost the Demand for Anti-inflammatory Biologics

The growing burden of inflammatory diseases, such as ulcerative colitis, rheumatoid arthritis, and psoriasis, has increased the demand for biologics in the U.S. anti-inflammatory biologics market. Furthermore, the swift utilization of biologics in terms of inflammatory disease treatment coupled with improved reimbursement trends for therapies with biologics is projected to fuel the market's growth. 

• For instance, according to a study published by NCBI in June 2021, the estimated prevalence of adult psoriasis in the U.S. was 7.6 million. Such a large population suffering from psoriasis is expected to boost the U.S. anti-inflammatory biologics market growth.

RESTRAINING FACTORS

Limited Preference for Anti-Inflammatory Biologics as the Initial Treatment to Impede the Adoption of These Drugs

Despite the high effectiveness of biologics in rheumatoid arthritis and psoriasis treatment, the lack of inclination for biologics compared to disease-modifying anti-rheumatic drugs (DMARDs) hampers the market growth of anti-inflammatory biologics in the U.S.

For the treatment of rheumatoid arthritis, disease-modifying anti-rheumatic drugs (DMARDs), which include drugs, such as methotrexate, are considered the first-line treatment. Similarly, topical drugs for psoriasis, including corticosteroids and vitamin D analogues, are used as first-line treatment.

• For instance, according to the Arthritis Foundation, in September 2022, the American College of Rheumatology recommended methotrexate over anti-inflammatory biologic as the first-line treatment for most individuals suffering from inflammatory autoimmune diseases, including rheumatoid arthritis and psoriatic arthritis.

Similarly, these drugs are used as a third line of treatment for rheumatoid and psoriatic arthritis. This is anticipated to substantially restrict the available patient pool for treatment, leading to the U.S. anti-inflammatory biologics market restraint in the forecast period.

U.S. Anti-Inflammatory Biologics Market Segmentation Analysis

By Drug Class Analysis

Based on the drug class, the market is segmented into anti-tumor necrosis factor (TNF), interleukin antagonists, janus kinase (JAK) inhibitor, and others.

The interleukin antagonists segment held the largest share and is anticipated to grow at a significant CAGR during the forecast period due to the rising prevalence of psoriasis and ulcerative colitis and increased patient visits to hospitals. Furthermore, the increased focus of market players on the research and development of Interleukin Inhibitors is expected to contribute to the segmental growth.

• For instance, Pfizer is developing a biologics, Dekavil (F8IL10). It is a fully human anti-inflammatory product consisting of the F8 antibody fused to interleukin-10 (IL10). The drug is currently in Phase II of its clinical trial.

By Application Analysis

Based on application, the market is divided into psoriasis, rheumatoid arthritis, and others.

The rheumatoid arthritis segment held the highest market share in 2022. The highest share is due to the growing cases of rheumatoid arthritis across the country and the growing focus of market players to develop more anti-inflammatory biologics for this indication.

• For instance, in October 2022, GSK plc provided an update on the ContRAst phase III programme for otilimab, an investigational monoclonal antibody in the potential treatment of moderate to severe rheumatoid arthritis. The ContRAst phase IIl programme enrolled a broad range of difficult-to-treat patients who had an inadequate response to available treatments.

By Route of Administration Analysis

By route of administration, the market for anti-inflammatory biologics is segmented into oral and injection. The injection segment is further sub-segmented into intravenous and subcutaneous segments.

The injection segment held the highest U.S. anti-inflammatory biologics market share in 2022. The growth is attributed to the maximum number of anti-inflammatory biologics administrated via subcutaneous or intravenous route, which is the primary reason for the dominant share of this segment.

By Distribution Channel Analysis

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The hospital pharmacies segment held the largest share and is expected to grow at a robust CAGR during the forecast period owing to the presence of a large patient population seeking treatment for inflammation-related disorders in hospitals, which increases the demand for drugs in hospital pharmacies. Furthermore, rising incidences and cases of rheumatoid arthritis is expected to boost the market in the forecast period.

List of Key Companies in U.S. Anti-Inflammatory Biologics Market

In terms of the competitive landscape, the market for anti-inflammatory biologics depicts the presence of established and emerging companies operating in the market. Leading players in the market, such as AbbVie Inc. and Johnson & Johnson Services, Inc., have a significant share. AbbVie Inc. is one of the prominent players in the market solely from the sales of an anti-tumor necrosis factor (TNF) product called Humira.

Some other companies with a considerable presence in the U.S. anti-inflammatory biologics market include Amgen Inc., Eli Lilly and Company, Pfizer Inc. and other small & medium-sized players. These companies are focusing on introducing and developing novel drugs in the market, which is expected to boost their market share.

LIST OF KEY COMPANIES PROFILED:

• AbbVie Inc. (U.S.)


• Merck & Co., Inc. (U.S.)


• Bristol-Myers Squibb Company (U.S.)


• Johnson & Johnson Services, Inc. (U.S.)


• Pfizer Inc. (U.S.)


• Novartis AG (Switzerland)


• Eli Lilly and Company (U.S.)


• Amgen Inc. (U.S.)


• Biogen (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• October 2023: The U.S. FDA announced the approval of BIMZELX (bimekizumab-bkzx) for treating moderate-to-severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy.


• September 2022: Bristol Myers Squibb announced two-year results from the POETYK PSO long-term extension (LTE) trial with continuous Sotyktu treatment in adult patients with plaque psoriasis.


• January 2022: AbbVie announced the U.S. FDA had approved RINVOQ for treating moderate to severe atopic dermatitis.

REPORT COVERAGE

The U.S. anti-inflammatory biologics market research report provides a detailed market analysis. The report provides information related to key industry developments such as mergers and acquisitions, and market dynamics. Additionally, it includes pipeline analysis, patent snapshot, and the epidemiology of key inflammatory disorders in the country. In addition, the impact of COVID-19 and the industry overview during the pandemic and post-pandemic are covered in the report.

Report Scope & Segmentation